Na v channels are essential for metazoan membrane depolarization, and Na v channel dysfunction is directly linked with epilepsy, ataxia, pain, arrhythmia, myotonia, and irritable bowel syndrome. Human Na v channelopathies are primarily caused by variants that directly affect Na v channel permeability or gating. However, a new class of human Na v channelopathies has emerged based on channel variants that alter regulation by intracellular signaling or cytoskeletal proteins. Fibroblast growth factor homologous factors (FHFs) are a family of intracellular signaling proteins linked with Na v channel regulation in neurons and myocytes. However, to date, there is surprisingly little evidence linking Na v channel gene variants with FHFs and human disease. Here, we provide, to our knowledge, the first evidence that mutations in SCN5A (encodes primary cardiac Na v channel Na v 1.5) that alter FHF binding result in human cardiovascular disease. We describe a five*generation kindred with a history of atrial and ventricular arrhythmias, cardiac arrest, and sudden cardiac death. Affected family members harbor a novel SCN5A variant resulting in p.H1849R. p.H1849R is localized in the central binding core on Na v 1.5 for FHFs. Consistent with these data, Na v 1.5 p.H1849R affected interaction with FHFs. Further, electrophysiological analysis identified Na v 1.5 p.H1849R as a gain-of-function for I Na by altering steady-state inactivation and slowing the rate of Na v 1.5 inactivation. In line with these data and consistent with human cardiac phenotypes, myocytes expressing Na v 1.5 p.H1849R displayed prolonged action potential duration and arrhythmogenic afterdepolarizations. Together, these findings identify a previously unexplored mechanism for human Na v channelopathy based on altered Na v 1.5 association with FHF proteins.
ion channel | channelopathy | atrial fibrillation | Nav1. 5 | FHF E ncoded by 10 different genes, Na v channel α-subunits regulate excitable membrane depolarization and are therefore central to metazoan physiology (1) . Na v channel function is critical for neuronal firing and communication (1, 2) , cardiac excitationcontraction coupling (3) , and skeletal and intestinal function (4, 5) . The impact of Na v channel function for human biology has been elegantly defined by nearly two decades of studies directly linking Na v channel gene variants with human disease. To date, the field of human Na v channelopathies has exploded to include wide spectrums of neurological [epilepsy (1), pain (6), ataxia (7)] and cardiovascular diseases (8) as well as myotonia congenital (9) and even irritable bowel syndrome (5) . Though the majority of these diseases are based on gene variants in Na v channel transmembrane segments that affect the channel pore or channel gating (10), a new paradigm for Na v channelopathies has emerged based on variants that alter association of Na v channels with essential regulatory proteins. To date, human Na v channel gene variants linked with neurological and cardiovascular disease have not only provided new insight on the pathophysiology of excitable cell disease, but also identified and/or validated key in vivo Na v channel regulatory pathways [syntrophin (11) , ankyrin-G (12, 13), Na v β1 (14) , calmodulin (15) , protein kinase A (16), and CaMKIIδ (17, 18) ]. However, in many cases, whereas animal and cellular findings may strongly support the role of regulatory proteins for human Na v channel function, human variants that may serve to validate the association have remained elusive, likely due to redundancy of signaling pathways or extreme severity of the disease.
Identified in the retina nearly two decades ago, fibroblast growth factor homologous factors (FHFs; FGF11-14) are a family of signaling proteins with key roles in ion channel regulation (19) . Distinct from canonical FGFs that are secreted and bind to extracellular FGF receptors, FGF11-14 lack signal sequences and thus regulate intracellular targets. Currently, Na v channels are the most characterized FHF target (20) (21) (22) , and recent structural data mapped the FHF binding site to the Na v channel C terminus (23, 24) . Notably, FHFs display multiple roles in Na v channel regulation, including expression, trafficking, and channel gating. However, each FHF appears to show unique regulatory roles for Na v channel regulation that are cell type and Na v channel isoform dependent. Though FHF signaling is complex, the roles of FHFs Significance Cardiovascular disease remains the leading cause of mortality in the United States, and cardiac arrhythmia underlies the majority of these deaths. Here, we report a new mechanism for congenital human cardiac arrhythmia due to defects in the regulation of the primary cardiac Na v channel, Na v 1.5 (SCN5A), by a family of signaling molecules termed fibroblast growth factor homologous factors (FHFs). Individuals harboring SCN5A variants that affect Na v 1.5/FHF interactions display atrial and ventricular phenotypes, syncope, and sudden cardiac death. The human variant results in aberrant Na v 1.5 inactivation, causing prolonged action potential duration and afterdepolarizations in murine myocytes, thereby providing a rationale for the human arrhythmia.
in vertebrate physiology are clearly illustrated by dysfunction of FHFs in human disease. To date, FHF loci have been linked with spinocerebellar ataxia 27, X-linked mental retardation, and cardiac arrhythmia (25-27). In animals, FHF deficiency results in severe neurological phenotypes associated with altered Na v channel function (28) . Despite the overwhelming biochemical, functional, and in vivo animal data linking Na v channels and FHF proteins, and in contrast to many other Na v channel regulatory pathways, there are surprisingly little data linking human Na v channel variants with FHFs in any disease.
Here we provide, to our knowledge, the first evidence that human Na v channel gene variants that alter FHF binding result in potentially fatal human disease. We describe a five-generation kindred with a history of atrial and ventricular arrhythmias, cardiac arrest, and sudden cardiac death. Genetic testing revealed a SCN5A variant, resulting in p.H1849R, in affected family members. The identified SCN5A variant p.H1849R is novel and located at a site in the Na v 1.5 C-terminal domain identified to associate with FHFs. Notably, the human p.H1849R variant markedly altered interaction with FHFs, and functional analysis of the variant identified Na v 1.5 p.H1849R as a gain-of-function variant. Further, consistent with LQT3 phenotypes observed in the family, expression of this variant resulted in prolonged action potential duration and arrhythmogenic afterdepolarizations. Together, our findings define a previously unidentified mechanism for human Na v channelopathies based on loss of Na v 1.5 association with FHF proteins and further confirm the critical link between these intracellular proteins and Na v channels in excitable cells.
Results
Na V 1.5 Variant p.H1849R Associates with LQT, Atrial Fibrillation, Ventricular Tachycardia, and Sudden Cardiac Arrest. We identified a previously uncharacterized SCN5A variant associated with atrial fibrillation (AF), long QT, and sudden cardiac arrest. The proband is a 27-y-old male who suffered sudden cardiac arrest at work while moving boxes. Upon resuscitation with CPR and automated external defibrillator (AED) shock, initial ECG recordings presented episodes of AF, evident by the lack of P-waves and a varying R-R interval, accompanied by prevalent premature ventricular contractions (PVCs; Fig. 1A , white arrows). Subsequent interrogations revealed a prolonged QT interval, with a corrected QT (QT c ) up to 496 ms (sinus rhythm), augmented by ST segment changes and episodes of AF. Procainamide challenge of the proband was negative for Brugada (BrS) ECG pattern, and did not demonstrate J-point elevation or QRS prolongation. Serial echocardiograms were unremarkable in terms of ventricular function and atrial and ventricular dimensions. A diagnosis of LQT3 was made after serial rest ECGs disclosed persistent QTc prolongation. Based on phenotypes and witnessed arrest, the proband was implanted with dual chamber implantable cardioverter defibrillator (ICD). The ICD has appropriately fired multiple times in response to sustained ventricular tachycardia/fibrillation (Fig. 1B) . Notably, several family members have presented cardiac abnormalities coincident with a family history of sudden cardiac death (SCD; Fig. 1C ). Due to the high suspicion for primary arrhythmia disease and documented family history of SCD, the proband underwent targeted genetic testing for identified arrhythmia genes (KCNQ1, KCNH2, SCN5A, ANK2, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP9, and SNTA1). No known disease-associated variants were identified. However, secondary testing identified a heterozygous A > G nucleotide substitution in exon 28 of the SCN5A gene, producing a histidineto-arginine change in Na v 1.5, the primary cardiac Na v channel ( Cascade screening showed that the proband's mother and sister harbored the Na v 1.5 p.H1849R variant ( and ventricular ectopy were recorded on a Holter monitor, and subsequently an ILR was placed for future interrogation. After positive genetic screening in the proband's sister, further screening for the proband's niece and nephew was indicated, and consent was given for testing. Genetic screening of the niece (5 y) was positive for the p.H1849R variant, and follow-up was initiated for electrophysiology study testing. A diagnosis of LQT3 was made after serial-rest ECGs disclosed persistent QTc prolongation (QTc 471 ms). Intermittent late-peaking T waves were also appreciated. Other significant family history included the proband's maternal grandfather who had SCD in his sleep at the age of 28, and a maternal paternal great grandfather who had SCD in his sleep at the age of 52. No autopsies were performed on these individuals, and no DNA is available for evaluation. Na v 1.5 p.H1849R Alters Association with FHFs. p.H1849 is located in the cytoplasmic C terminus of Na v 1.5 (Na v 1.5 CT) and conserved across species (Fig. 1 E and F) . This specific residue was previously identified as forming part of the binding pocket for FHFs (23) . A rendering of the interaction surfaces for FGF13 and the Na v 1.5 CT demonstrates a critical association between FGF13 Arg57 with its interaction pocket anchored by residue H1849 on the Na v 1.5 CT (Fig. 2 A and B) . We tested the impact of p.H1849R on Na v 1.5/ FHF interactions. Coimmunoprecipitation experiments using detergent-soluble lysates from mouse heart confirmed interaction of Na v 1.5 with FGF13 ( Fig. 2 C and D) . Further, pull-down experiments from detergent-soluble lysates from mouse heart demonstrated direct association of GST-Na v 1.5 C terminus with FGF13 (Fig. 2E) . The p.H1849R variant altered the interaction with FHFs. First, in the context of a GST-Na v 1.5 CT fusion protein, the variant reduced binding for FGF13 from detergent-soluble lysates from mouse heart (Fig. 2E) . We observed no binding of GST alone for FGF13. Second, in vitro binding assays demonstrated similar results with all FHFs: radiolabeled FGF12, FGF13, and FGF14 all showed reduced interaction with GST-Na v 1.5 CT harboring the p.H1849R variant or GST alone (Fig. 2F) . We quantified the impact of the Na v 1.5 p.H1849R variant on FHF binding using isothermal titration calorimetry. Purified WT Na v 1.5 C terminus and FGF13 associated with high affinity (K d = 17 nM; Table S1 ; Fig. 2G ). In contrast, purified Na v 1.5 C terminus p.H1849R showed ∼100-fold decrease in affinity for purified FGF13 (K d = 1.9 μM; Table S1; Fig. 2 H and  I) . In summary, Na v 1.5 p.H1849R is associated with familial arrhythmias and significantly alters the interaction of Na v 1.5 with FHF family proteins. To analyze the consequences of altered interaction between the Na v 1.5 p.H1849R variant and FHFs on select I Na properties, we created a new mouse model for inducible cardiomyocyte Na v 1.5 silencing. Scn5a knock-in mice were created with loxP sites flanking Scn5a exons 10 and 13 ( Fig. S1 ) to silence Scn5a expression in the presence of Cre recombinase. Following birth, cardiomyocytes isolated from neonatal Scn5a f/f mice were cultured and analyzed for Na v 1.5-dependent current ± Adv-Cre transduction. Though we observed robust I Na in mock-transduced myocytes, we detected only negligible I Na in cultures transduced with Adv-Cre (Fig. S1 ). Consistent with these data, we observed diminished Na v 1.5 by immunoblot and immunostaining of Adv-Cre-infected myocytes (Fig. S1 ). Despite I Na loss, myocytes remained healthy and viable. Notably, introduction of exogenous WT Na v 1.5 in these cultures resulted in rescue of I Na to approximately physiological levels (Scn5a f/f myocyte I Na,peak : 115.2 ± 8.4 pA/pF; Scn5a f/f + Adv-Cre + Na v 1.5 I Na , peak : 142.2 ± 18.2 pA/pF). Thus, this new system is sufficient to analyze I Na properties of putative Na v 1.5 variants.
Na v 1.5 p.H1849R Alters Na v 1.5 Steady-State Inactivation in Primary
Myocytes. FHF proteins regulate Na v channel steady-state inactivation (21, 29) , and knockdown of FHFs in cardiomyocytes results in a hyperpolarizing shift in steady-state interaction (24, 27) . We therefore used the Scn5a f/f myocyte system to test the human Na v 1.5 H1849R variant for alterations in I Na inactivation properties. As noted above, I Na levels in Adv-Cre-infected Scn5a f/f myocytes (GFP-positive) are rescued by expression of exogenous Na v 1.5 (Fig.  3A) . Of note, expression of Na v 1.5 p.H1849R at equivalent levels resulted in an increased I Na density relative to WT Na v 1.5 ( Fig. 3A ; increased ∼34%; P < 0.05). Further, we observed a significant ∼6.7-mV depolarizing shift in the V 1/2 of voltage-dependent inactivation of the p.H1849R variant compared with the WT channel (−101.2 vs. −107.9 mV; P < 0.05; Fig. 3B ). Because FHF knockdown in cardiomyocytes leads to a hyperpolarizing shift in steadystate inactivation, these results suggested that the p.H1849R variant maintains an altered interaction with FHFs despite the reduced affinity noted in binding experiments with the isolated Na v 1.5 CT and FHFs (Fig. 2) . We observed no difference in voltage dependence of activation of WT Na v 1.5 compared with Na v 1.5 p.H1849R (Fig. 3B) , consistent with the lack of effect of FHFs on Na v 1.5 interaction in cardiomyocytes (24) . In summary, consistent with past work linking FHFs with regulation of Na v channel steadystate inactivation (21, 24, 27, 29) , Na v 1.5 p.H1849R displays aberrant steady-state inactivation in primary myocytes. Na v 1.5 p.H1849R Displays Arrhythmogenic I Na Properties. Patients harboring SCN5A variants with LQT3 display signature QT interval prolongation associated with altered Na v 1.5 regulation. To date, two molecular mechanisms underlying aberrant I Na regulation in LQT3 are described. LQT3 is primarily caused by SCN5A variants that alter the fast inactivation gate of I Na , resulting in channels that may reopen at later stages of the action potential (30). This depolarizing "late" I Na current thus extends ventricular depolarization, often resulting in arrhythmogenic afterdepolarizations. Alternatively, human LQT3 may also be linked with SCN5A variants that slow Na v 1.5 channel inactivation (individual channels with longer open state duration) (31, 32) , again extending ventricular depolarization and creating a substrate for arrhythmogenic afterdepolarizations.
To identify potential pathogenic mechanisms of the human Na v 1.5 H1849R variant in the complete absence of any potentially competing ionic currents, we analyzed I Na signatures of WT Na v 1.5 and Na v 1.5 p.H1849R coexpressed with FGF12 in HEK293 cells (SI Materials and Methods). FGF12 was chosen as the FHF for this assay as it is the most abundant FHF in human heart (27) . Consistent with findings in myocytes, we observed increased I Na,peak for Na v 1.5 p.H1849R compared with WT Na v 1.5 ( Fig. 3C ; P < 0.05). Further, we observed a depolarizing shift in steady-state inactivation for Na v 1.5 p.H1849R compared with WT Na v 1.5 ( Fig. 3D ; ∼9-mV shift for Na v 1.5 p.H1849R relative to WT; −67.7 ± 1.9 vs. −76.8 ± 1.9 mV, respectively; P < 0.05). We did not observe differences in activation between Na v 1.5 and Na v 1.5 p.H1849R [ Fig. 3E ; WT: −57.1 ± 2.5 mV, p.1849R: −56.0 ± 1.5 mV; P = not significant (N.S.)]. Most notably, we observed a striking slowing of inactivation of Na v 1.5 p.H1849R compared with WT Na v 1.5 (Fig. 3 F and G; ∼fivefold increase in decay time for Na v 1.5 p.H1849R compared with WT Nav1.5; P < 0.05). In summary, the Na v 1.5 p.H1849R variant has a number of gain-of-function phenotypes contributing to its arrhythmogenic properties, most notably a slowed rate of inactivation. Na v 1.5 H1849R Alters Myocyte Membrane Excitability. Action potentials (APs) were measured in myocytes expressing WT Na v 1.5 or Na v 1.5 p.H1849R to define the relationship between the human variant and myocyte membrane excitability. In line with alterations in I Na observed in both myocytes and heterologous cells, we observed a significant increase in AP duration (APD) at 90% repolarization (APD 90 ) for myocytes expressing Na v 1.5 p.H1849R compared with WT Na v 1.5-expressing myocytes (Fig. 4 A and B ; P < 0.05). We observed no difference in resting membrane potential or peak transmembrane potential between the two groups (P = N.S.). Notably, consistent with the significant differences in APD 90 , we observed spontaneous depolarizations (Fig. 4 C and D) in Na v 1.5 p.H1849R myocytes but not in myocytes expressing WT Na v 1.5 (WT Na v 1.5: 0% myocytes; Na v 1.5 p.H1849R: ∼43% myocytes; P < 0.05). In summary, consistent with altered I Na and the human LQT3 phenotype, Na v 1.5 p.H1849R results in APD prolongation and arrhythmogenic spontaneous membrane afterdepolarizations.
Discussion
Cardiac ion channel dysfunction is tightly linked with congenital human arrhythmias. Though mutations in ion channel pore and gating regions represent the vast majority of pathogenic variants, a second class of arrhythmia variants alter the regulation of ion channels by cytosolic signaling or scaffolding proteins. In fact, these findings have revealed new paradigms for rare forms of human arrhythmia based on defects in ion channel-associated proteins. By integrating human clinical and genetic data with biochemical, cell biological, and electrophysiology findings, we identify a new mechanism for human cardiac Na v channelopathy based on loss of binding to the FHF family of ion channel regulatory proteins. Individuals harboring the Na v 1.5 p.H1849R variant display LQT3 and AF. Functionally, Na v 1.5 p.H1849R displays an altered interaction with FHFs, resulting in increased I Na peak, increased Na v 1.5 channel availability and, most critically, slowed inactivation. Together, these parameters provide a rationale for the human cardiac phenotypes. In summary, these new findings directly validate the FHF family of signaling proteins as critical for human cardiac excitability. Further, these data illustrate the likely multifunctional roles of FHF proteins for the regulation of membrane excitability across diverse cell types.
The FHFs have gained significant attention due to their role in regulating Na v and Ca v channels (24, 29, (33) (34) (35) (36) , as well as their links with human excitable cell disease. In neurons, FHF dysfunction has been linked with aberrant I Na phenotypes and human FGF14 variants cause spinocerebellar ataxia 27 (25). Further, the FGF13 locus has been linked with nonspecific forms of X-linked mental retardation (26) . Finally, relevant for this study, a missense variant in FGF12 linked with aberrant Na v 1.5 function was recently associated with Brugada syndrome (27) . However, to date, no human Na v channel variants that alter association with FHF proteins have been linked with human disease. Of note, though FGF12-14 all directly associate with Na v channels, each display unique Na v channel regulatory properties that may differentially tune Na v channel expression, trafficking, current density, availability, and/or persistent current (I Na,L ), depending on the cell type and Na v channel isoform (29, 33, 34) . Given these data, the differences in clinical phenotypes are not surprising, but raise important caveats regarding data interpretation.
The molecular mechanisms underlying human LQT3 may be multifactorial but are generally classified into two categories. The primary mechanism underlying LQT3 is altered Na v 1.5 fast inactivation (30) . As noted above, in this mechanism, mutant Na v 1.5 channels display an increased probability for reopening, resulting in inward depolarizing I Na during the plateau phase of action potential (I Na,late ), lengthening of repolarization, and susceptibility to arrhythmogenic afterdepolarizations. However, though less common, slowed inactivation, resulting in Na v 1.5 channels with increased time in the open state, may also underlie LQT3 (31, 32) . In our study, Na v 1.5 p.H1849R resulted in increased peak I Na and increased I Na availability (37, 38) , consistent with known roles of FHFs in channel gating and/or internalization (21, 29) . Most notably, the human Na v 1.5 p.H1849R variant displayed a striking signature of slow inactivation compared with WT Na v 1.5. Consistent with these data, compared with WT Na v 1.5, myocytes harboring the Na v 1.5 p.H1849R displayed increased APD and spontaneous afterdepolarizations even in the absence of adrenergic stimulation. Thus, our findings illustrate that Na v 1.5 p.H1849R is an I Na gain-of-function mutation through the slowing of the rate of inactivation and increasing Na v 1.5 availability during the AP plateau phase, thus prolonging APD and producing proarrhythmic afterdepolarizations. These findings are consistent with prior reports linking I Na slow inactivation and increased availability with both LQT3 (31, 32) and AF (38) as well as LQT associated with α1 syntrophin gene variants (37) .
In summary, our data provide, to our knowledge, the first evidence for human disease based on Na v channel gene variants that block FHF regulation. Our combined data support altered FHF binding as the mechanism for arrhythmia for Na v 1.5 p.H1849R. Further, recent unbiased structural data identify Na v 1.5 H1849 as a central residue for Na v 1.5/FHF association. Although the endogenous concentrations of FHFs and Na v channel α-subunits in cardiomyocytes are not known, it is reasonable to assume that an ∼100-fold decrease in affinity between the core domain of the FHF and the mutant Na v 1.5 C-terminal domain (CTD), the key interaction sites identified on each molecule (23), would affect FHFdependent channel function. This hypothesis is consistent with the previous observation that an affinity-reducing mutation within the FHF core, at the Na v channel interaction site, similarly confers altered Na v channel function in neurons (36) . However, we note that this variant may also alter Na v 1.5 folding and biophysical function independent of, or in conjunction with, FHF-mediated effects. Again, it will be critical in future in vivo experiments to dissect these specific points. In closing, our findings underscore the complexity and heterogeneity in the presentation of congenital arrhythmia, particularly as it relates to Na v 1.5 and its growing list of regulatory proteins.
Materials and Methods
Approval for use of human subjects was obtained from the Institutional Review Board of Ohio State University, and subjects provided informed consent. Genomic DNA was extracted from peripheral blood lymphocytes of the proband, proband's sister, mother, niece, and grandmother. A full LQTS genetic panel screened for mutations in 12 known disease-causing genes: KCNQ1, KCNH2, SCN5A, ANK2, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP9, and SNTA1. Sequencing identified a heterozygous A > G nucleotide transition in exon 28 in the SCN5A gene, producing a histidine-to-arginine amino acid change at the 1849 residue in the Na V 1.5 protein.
For animal experiments, animals were handled according to approved protocols and animal welfare regulations of the Institutional Animal Care and Use Committee of The Ohio State University. Detailed descriptions of all materials and methods are provided in SI Materials and Methods.
